In the randomized phase III Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations (OlympiAD) study evaluating olaparib vs. treatment of physician’s choice in patients with metastatic breast cancer and a BRCA mutation, patients with treated, stable CNS metastases were eligible. This evidence concerns the gene BRCA1 and breast carcinoma.